Deferasirox in mucormycosis: hopefully, not defeated.
نویسندگان
چکیده
References 1 Li C, Kuti JL, Nightingale CH et al. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005; 56: 388–95. 2 Roberts JA, Norris R, Paterson DL et al. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2011; doi: 10.1111/ j.1365-2125.2011.04080.x. 3 Seyler S, Cotton F, Taccone FS. Recommended b-lactam regimens are insufficient in septic patients treated with continuous renal replacement therapy. Crit Care 2011; 15: R137. 4 EUCAST Clinical Breakpoints for Enterobacteriaceae. http://www.eucast. org/clinical_breakpoints/ (October 2011, date last accessed). 5 Product Information, Tazocin (piperacillin/tazobactam). Wyeth Pharmaceuticals Inc., Madison, NJ, USA, 02.10.2006. http://www.pfizer. ca/en/our_products/products/monograph/273 (October 2011, date last accessed). 6 Newman D, Scheetz MH, Adeyemi OA et al. Serum piperacillin/ tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother 2007; 41: 1734–9.
منابع مشابه
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes...
متن کاملThe iron chelator deferasirox protects mice from mucormycosis through iron starvation.
Mucormycosis causes mortality in at least 50% of cases despite current first-line therapies. Clinical and animal data indicate that the presence of elevated available serum iron predisposes the host to mucormycosis. Here we demonstrate that deferasirox, an iron chelator recently approved for use in humans by the US FDA, is a highly effective treatment for mucormycosis. Deferasirox effectively c...
متن کاملCombination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.
Liposomal amphotericin B (LAmB) combined wither either micafungin or deferasirox was synergistic in previous murine studies with mucormycosis or aspergillosis. We hypothesized that triple therapy using LAmB, micafungin, and deferasirox could further improve outcomes of mucormycosis or aspergillosis. Triple therapy improved survival and reduced tissue fungal burden of mice with mucormycosis and ...
متن کاملRecent Advances in the Treatment of Mucormycosis
In recent years, substantial advances have been achieved in the treatment of mucormycosis. It is now clear that early initiation of therapy results in substantially better outcomes, underscoring the need to maintain a high index of suspicion and aggressively biopsy potential lesions. Increasing data support the need for surgical excision of infected and/or necrosed tissue whenever feasible. Bas...
متن کاملRecent advances in the management of mucormycosis: from bench to bedside.
Recent therapeutic advances have the potential to improve outcomes of mucormycosis. Lipid formulations of amphotericin B (LFAB) have evolved as the cornerstone of primary therapy for mucormycosis. Posaconazole may be useful as salvage therapy, but it cannot be recommended as primary therapy for mucormycosis on the basis of available data. Preclinical and limited retrospective clinical data sugg...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of antimicrobial chemotherapy
دوره 67 3 شماره
صفحات -
تاریخ انتشار 2012